A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

被引：11
|
作者：
Hertzberg, Mark
Ku, Matthew
Catalani, Olivier
Althaus, Betsy
Simko, Stephen
Gregory, Gareth P.
机构：
[1] Prince Wales Hosp, Sydney, NSW, Australia
[2] St Vincents Hosp, Melbourne, Vic, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Genentech Inc, San Francisco, CA 94080 USA
[6] Monash Univ, Sch Clin Sci Monash Hlth, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS7575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7575
引用
收藏
页数：3
相关论文
共 50 条
  • [1] POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Haioun, Corinne
    Matasar, Matthew J.
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hernandez, Juana
    Perretti, Thomas
    McMillan, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis
    Ip, Andrew
    Munoz, Javier
    Rosenthal, Allison C.
    Darrah, Justin M.
    Wang, Tongsheng
    Zhang, Guihua
    Mutebi, Alex
    Jun, Monika
    Ding, Zhijie
    Chhibber, Anindit
    Navarro, Fernando Rivas
    Risum, Malene
    Atiya, Mohammad
    Brodkin, Samantha
    Wang, Anthony W.
    Alshreef, Abualbishr
    Harb, Diala
    Sacchi, Mariana
    Hoehn, Daniela
    Karimi, Yasmin H.
    BLOOD, 2024, 144 : 7757 - 7758
  • [3] Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Matasar, Matthew J.
    Haioun, Corinne
    Sancho, Juan-Manuel
    Viardot, Andreas
    Izquierdo, Antonia Rodriguez
    Martin, Eva Maria Donato
    Garcia-Sancho, Alejandro Martin
    Sandoval-Sus, Jose David
    Tilly, Herve
    Vandenberghe, Elizabeth
    Hirata, Jamie
    Choudhry, Priya
    Chang, Yi Meng
    Musick, Lisa
    McMillan, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Maakaron, Joseph
    Asch, Adam S.
    Popplewell, Leslie L.
    Collins, Graham P.
    Flinn, Ian W.
    Ghosh, Nilanjan
    Keane, Colin
    Ku, Matthew
    Mehta, Amitkumar
    Roschewski, Mark
    O'Hear, Carol
    Ren, Xuehan
    Villa, Bertha
    Lal, Indu
    Smith, Sonali M.
    Advani, Ranjana H.
    BLOOD, 2022, 140 : 3728 - 3730
  • [5] Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant
    Fox, David
    El Moustaid, Fadoua
    Masaquel, Anthony
    Rosettie, Katherine L.
    Celik, Hazal
    Cassoli, Lourenia
    Flowers, Christopher R.
    BLOOD, 2024, 144 : 5027 - 5028
  • [6] Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Castro, Felipe
    Surinach, Andy
    Launonen, Aino
    Thuresson, Per-Olof
    Felizzi, Federico
    BLOOD, 2020, 136
  • [7] POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Matasar, Matthew J.
    Haioun, Corinne
    Sancho, Juan-Manuel
    Viardot, Andreas
    Hirata, Jamie
    Perretti, Thomas
    Musick, Lisa
    McMillan, Andrew K.
    BLOOD, 2021, 138
  • [8] SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Westin, Jason
    Olszewski, Adam J.
    Fogliatto, Laura Maria
    Kim, Won-Seog
    Shin, Ho-Jin
    Wu, Hao
    Yin, Shen
    Pham, Song
    Penuel, Elicia
    Jing, Jing
    Wei, Michael C.
    Budde, Elizabeth L.
    BLOOD, 2022, 140 : 3771 - 3772
  • [9] Azacytidine plus rituximab-gemcitabine-oxaliplatin as salvage treatment in patients with relapsed/ refractory diffuse large B-cell lymphoma
    Meng Fanqiao
    Xiang Maoyuan
    Peng Cuicui
    Liu Yu
    Zeng Dongfeng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S453 - S453
  • [10] Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis
    Munoz, Javier
    Rosenthal, Allison C.
    Ip, Andrew
    Darrah, Justin M.
    Wang, Tongsheng
    Zhang, Guihua
    Mutebi, Alex
    Jun, Monika
    Ding, Zhijie
    Chhibber, Anindit
    Navarro, Fernando Rivas
    Risum, Malene
    Atiya, Mohammad
    Brodkin, Samantha
    Wang, Anthony W.
    Alshreef, Abualbishr
    Harb, Diala
    Sacchi, Mariana
    Hoehn, Daniela
    Karimi, Yasmin H.
    BLOOD, 2024, 144 : 7760 - 7761
12345